A Clinical Study of <i>Mandura Bhasma</i> (Iron Oxide Based Nanomedicine) Prepared by Two Different <i>Bhavana Dravya</i> (Trituration Media) Methods on <i>Pandu Roga</i> with Special Reference to Iron Deficiency Anaemia

Introduction: Drugs are essential component of the Chatus pada (four pillars of treatment) as emphasized by Acharya Charaka, who placed them second to the physician out of 4 fundamental components of disease treatment that is Physician, Medicine, Attendant and Patients. This highlights the significance of the drug. In Ayurveda, drugs are mainly classified in plant, animal and metal-minerals origin. Apart from plants and animal origin drugs, metals-mineral drugs are unique in nature because of its usefulness in small quantities, not produce any nausea taste and gives quick relief in acute disease conditions. Bhasma is a unique dosages forms in ayurvedic pharmaceutics in which raw metals and minerals drugs are converted into assimilable and absorbable forms through different steps of process. Mandura Bhasma is one of important iron oxides-based herbo-mineral dosage form used for various ailments and specially in Pandu roga. The description about Pandu Roga is available in several texts like In Atharveda and Rigveda, Puranas, Mahabharat, Charaka Samhita, Sushruta Samhita, Rasatarangini and other text of Rasa-shastra. In modern era Pandu roga corelated with anaemic condition on the basis of disease manifestation. Iron deficiency Anaemia has been the main cause of health burden in India for the past decade on the basis of review on Global Burden of Disease (GBD) survey. Therefore, the present study was framed to know efficacy of two samples of Mandura Bhasma prepared by two different bhawana dravya methods on Pandu roga with special emphasis on Iron Deficiency Anaemia (IDA). Methods: A total of 60 patients was randomized selected on the basis of inclusion criteria and equally divided into 2 groups (30 patients in each group). Mandura Bhasma prepared with Bhavana of kumari swarasa was given to group A patients per orally in a dose of 250 mg twice a day for 112 days in a follow up interval of 28 days. In similar way group B patients were given Triphal kwatha bhavita mandur

View article page

Download PDF